Pabrinex shortage and guidance on alternatives
Pabrinex IV will be out of stock from July/ August 2024 until September 2025, due to supply issues relating to manufacturing regulations issued by the EU. Pabrinex IM will be permanently discontinued from December 2024. Pabrinex is only used in the UK, with thiamine IV/ IM being routinely used globally.
It is important to note if a Patient Group Direction (PGD) is being used (often used in community setting), only licensed products can be used in this setting. Therefore IM Pabrinex should be conserved for this purpose.
The following has been published online by the DHSC Specialist Pharmacy Service.
Joanna Henry, Gastroenterology Directorate Pharmacist, Liverpool University Hospitals NHS Trust
Sital Shah, Chair British Hepatology Pharmacy Group , Consultant Pharmacist, King’s College Hospital, London
Notice of Annual General Meeting 2025
Notice is hereby given that the Annual General Meeting (Meeting) of the British Society of Gastroenterology (Company) will be held at the Scottish Event Campus (SEC), Exhibition Way, Glasgow G3 8YW, on Wednesday 25 June 2025 at 6.10pm, in Room M1.
Help Shape the Future of GI Physiology – National Data Collection Open (May–June 2025)
The second National Data Collection for GI Physiology services will run from Monday 12th May to Friday 6th June 2025.
BSG Inflammatory Bowel Disease Surveillance Guideline 2025
Our newly updated guideline for colorectal surveillance for patients with IBD is now available, providing a comprehensive road map for evidence-based, expert management of the whole pathway to try and prevent or detect bowel cancer early for this higher risk patient group.